OBJECTIVE: To describe the burden of pediatric tuberculosis (TB) in a HIV-infected population and explore the demographic and clinical factors associated with the occurrence of pediatric TB. DESIGN: Longitudinal analysis of a cohort of HIV-infected children. METHODS: The endpoint of the study was clinically diagnosed TB. Cox proportional hazard regression was used to explore the predictors of incident TB among HIV-infected children under age 15 years after enrollment into the HIV program. RESULTS: The cohort comprised of 5040 children [median age: 5 years, interquartile range (IQR) 1-9 years]. During a median follow-up of 0.8 (IQR 0.1-2.5) years, 376 out of 5040 children met the case definition for TB. The overall incidence of TB was 5.2/100 person-years. In multivariate analyses, older age at enrollment [relative risk (RR) 1.7, 95%, confidence interval (CI) 1.5-1.8], severe wasting (RR 1.8, 95% CI 1.3-2.5), severe immune suppression (RR 2.6, 95% CI 1.8-3.8), anemia (RR 1.4, 95% CI 1.0-1.9) and WHO stage IV (RR 4.5, 95% CI 2.4-8.5) were all independently associated with a higher risk of TB. In addition, the use of antiretroviral drugs for more than 180 days reduced the risk of TB by 70% (RR 0.3, 95% CI 0.2-0.4). CONCLUSIONS: Antiretroviral therapy (ART) use is strongly associated with a reduced risk of tuberculosis among HIV-infected children, and should therefore be included in HIV care and treatment programs. Trials of interventions designed to improve the nutritional and hematologic status of these children should also be performed.
OBJECTIVE: To describe the burden of pediatric tuberculosis (TB) in a HIV-infected population and explore the demographic and clinical factors associated with the occurrence of pediatric TB. DESIGN: Longitudinal analysis of a cohort of HIV-infectedchildren. METHODS: The endpoint of the study was clinically diagnosed TB. Cox proportional hazard regression was used to explore the predictors of incident TB among HIV-infectedchildren under age 15 years after enrollment into the HIV program. RESULTS: The cohort comprised of 5040 children [median age: 5 years, interquartile range (IQR) 1-9 years]. During a median follow-up of 0.8 (IQR 0.1-2.5) years, 376 out of 5040 children met the case definition for TB. The overall incidence of TB was 5.2/100 person-years. In multivariate analyses, older age at enrollment [relative risk (RR) 1.7, 95%, confidence interval (CI) 1.5-1.8], severe wasting (RR 1.8, 95% CI 1.3-2.5), severe immune suppression (RR 2.6, 95% CI 1.8-3.8), anemia (RR 1.4, 95% CI 1.0-1.9) and WHO stage IV (RR 4.5, 95% CI 2.4-8.5) were all independently associated with a higher risk of TB. In addition, the use of antiretroviral drugs for more than 180 days reduced the risk of TB by 70% (RR 0.3, 95% CI 0.2-0.4). CONCLUSIONS: Antiretroviral therapy (ART) use is strongly associated with a reduced risk of tuberculosis among HIV-infectedchildren, and should therefore be included in HIV care and treatment programs. Trials of interventions designed to improve the nutritional and hematologic status of these children should also be performed.
Authors: Sheila Isanaka; Ferdinand Mugusi; Willy Urassa; Walter C Willett; Ronald J Bosch; Eduardo Villamor; Donna Spiegelman; Christopher Duggan; Wafaie W Fawzi Journal: J Nutr Date: 2011-12-21 Impact factor: 4.798
Authors: Rochelle P Walensky; Lindsey L Wolf; Robin Wood; Mariam O Fofana; Kenneth A Freedberg; Neil A Martinson; A David Paltiel; Xavier Anglaret; Milton C Weinstein; Elena Losina Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Paula Braitstein; Winstone Nyandiko; Rachel Vreeman; Kara Wools-Kaloustian; Edwin Sang; Beverly Musick; John Sidle; Constantin Yiannoutsos; Samwel Ayaya; E Jane Carter Journal: Pediatr Infect Dis J Date: 2009-07 Impact factor: 2.129
Authors: Neil A Martinson; H Moultrie; R van Niekerk; G Barry; A Coovadia; M Cotton; A Violari; G E Gray; R E Chaisson; J A McIntyre; T Meyers Journal: Int J Tuberc Lung Dis Date: 2009-07 Impact factor: 2.373
Authors: Rudi Wisaksana; Rachmat Sumantri; Agnes R Indrati; Aleta Zwitser; Hadi Jusuf; Quirijn de Mast; Reinout van Crevel; Andre van der Ven Journal: BMC Infect Dis Date: 2011-08-09 Impact factor: 3.090
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Enju Liu; Abel Makubi; Paul Drain; Donna Spiegelman; David Sando; Nan Li; Guerino Chalamilla; Christopher R Sudfeld; Ellen Hertzmark; Wafaie W Fawzi Journal: AIDS Date: 2015-07-17 Impact factor: 4.177
Authors: Lisa V Adams; Thomas McQuillan; Helga E Naburi; Goodluck Lyatuu; Matthew M Ippolito; Andrew Saunders; Anna Kiravu; Paul Palumbo; C Fordham von Reyn Journal: Pediatr Infect Dis J Date: 2014-12 Impact factor: 2.129
Authors: Stephen M Graham; Luis E Cuevas; Patrick Jean-Philippe; Renee Browning; Martina Casenghi; Anne K Detjen; Devasena Gnanashanmugam; Anneke C Hesseling; Beate Kampmann; Anna Mandalakas; Ben J Marais; Marco Schito; Hans M L Spiegel; Jeffrey R Starke; Carol Worrell; Heather J Zar Journal: Clin Infect Dis Date: 2015-10-15 Impact factor: 9.079
Authors: Stephen M Graham; Charalambos Sismanidis; Heather J Menzies; Ben J Marais; Anne K Detjen; Robert E Black Journal: Lancet Date: 2014-03-24 Impact factor: 79.321
Authors: Frederick Haraka; Tracy R Glass; George Sikalengo; Anna Gamell; Alex Ntamatungiro; Christoph Hatz; Marcel Tanner; Hansjakob Furrer; Manuel Battegay; Emilio Letang Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Enju Liu; Christopher Duggan; Karim P Manji; Roland Kupka; Said Aboud; Ronald J Bosch; Rodrick R Kisenge; James Okuma; Wafaie W Fawzi Journal: J Int AIDS Soc Date: 2013-08-13 Impact factor: 5.396